Evidence map›Paper›PMID 42699016›Full record

ArticleRare tumors2026

Bilateral breast metastatic rectal cancer with MET gene amplification: A rare case report.

Dung Thi Nguyen, Thanh Huy Nguyen, Ha Thu Le, Hien Thu Truong

Abstract readCase Reports
In one paragraph

Article in Rare tumors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dung Thi NguyenOn-demand GI Medical Oncology Department, Hanoi Oncology Hospital, Ha Noi, Viet Nam.ORCID https://orcid.org/0000-0001-5798-8636
Thanh Huy NguyenOn-demand GI Medical Oncology Department, Hanoi Oncology Hospital, Ha Noi, Viet Nam.ORCID https://orcid.org/0009-0008-1652-0832
Ha Thu LeOn-demand GI Medical Oncology Department, Hanoi Oncology Hospital, Ha Noi, Viet Nam.ORCID https://orcid.org/0009-0002-5868-5471
Hien Thu TruongOn-demand GI Medical Oncology Department, Hanoi Oncology Hospital, Ha Noi, Viet Nam.ORCID https://orcid.org/0009-0006-5766-0220

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast metastases originating from colorectal cancer are extremely rare, accounting for <0.5% of all malignant lesions of the breast and are often associated with histopathological forms with a poor prognosis, such as mucinous or signet-ring cells, in which bilateral breast metastases are even rarer. In this case report, we present a female patient in her early 50s. In April 2023, the patient was diagnosed with cT3N2M0 rectal cancer. After that, the patient underwent Miles surgery, followed by 12 cycles of mFOLFOX6 adjuvant chemotherapy, and received adjuvant chemoradiation therapy (50.4 Gy plus Capecitabine). The patient was discharged in January 2024. However, 7 months later, due to a palpable mass in her breast, the patient was found to have bilateral breast lesions and peritoneal metastases. Biopsies were taken from the lesions in both breasts and immunohistochemistry revealed that the tumors originated from the rectum with genetic testing detecting MET gene amplification. Thereafter, the patient was treated with many regimens, but the disease did not respond and progressed rapidly. The patient died six months after the recurrence of the disease was detected. In conclusion, breast metastases are a poor prognostic feature for colorectal cancer. Patients presenting with malignant breast lesions and a history of non-breast malignancy require careful differential diagnosis.

Indexed as

bilateral breast metastasescase reportcolorectal cancerMET gene amplificationpoor prognosis

Identifiers

PMID42699016
PMCPMC13542538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.